BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35…
BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026.
BioAtla to retain 65% ownership of Oz-V across all solid… [15030 chars]
Source: GlobeNewswire | Published: 2025-12-31T12:00:00Z
Credit: GlobeNewswire
